Company Announcements HalcyGen Pharmaceuticals Ltd ACN 115 832 963
‘A strategic license based partnership with Mayne Pharma International'
HGN_SUBA_UK PK Study Results - 2 March 2010
Warner Chilcott Quarter Results Doryx - 2 March 2010
Appendix 4C Quarterly Cash Flow - 29 January 2010
Ammended Paragraph IV Notice - 11 January 2010
Halcygen Distribution Notice - 15 December 2009 Mayne Pharma Acquisition Complete - 18 November 2009 Mayne Pharma Acquisition Announcement - 28 September 2009 HGN Mayne Pharma Acquisition Presentation - 25 September 2009 European Registration Strategy - 22 July 2009 ASX PK Dose Completion - 21 November 2008 ASX First Successful Pivotal PK Trial_16 October 2008 ASX PK Dose Completion_17 July 2008 CEO Forum Series Lunch ASX Ind Approval June 2008 ASX Oncology June_11_2008 Clinical Development and Registration of SubaItraconazole ASX Itraconazole Commercial Scale Manufacture Potential Application for Subazole in Oncology FDA Provides Guidance on Registration Study Results of the Annual General Meeting Held 20 November 2007 Appointment of Non- Executive Director Successful second Clinical Study for SUBA-Itraconazole HalcyGen anti-fungal drug passes clinical test - to enter Phase III trial in 2007/08 [PDF] Subscribe For Company Announcements
|
|
| 
